By Catherine Eckford (European Pharmaceutical Review)2023-09-25T14:53:53
Novartis’ radioligand therapy (RLT) is the first to demonstrate clinically meaningful benefit in a first line setting.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-14T12:32:00Z
Sponsored by Thermo Fisher Scientific
2026-04-14T12:29:00Z
Sponsored by JRS Pharma, In association with Vetter Pharma
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-04-15T15:00:00 2026-04-15T16:00:00
Sponsored by Thermo Fisher Scientific
2025-09-17T08:00:00
Sponsored by Mastercontrol
2026-03-04T15:00:00 2026-03-04T16:00:00
Sponsored by METTLER TOLEDO
2025-09-24T15:24:00
Sponsored by Lonza
Site powered by Webvision Cloud